resembles the action of sodium cromoglycate in the prophylaxis of atopic asthma in cases where mast cell stabilisation prevents the release of histamine and other mediators on antigen challenge. Ketotifen has been shown to be effective in blocking antigeninduced bronchoconstriction in adults,2 and longterm studies have shown useful prophylaxis can be achieved in a proportion of atopic asthmatics with increasing effects over a period of up to 3 months3 (J Pepys, E Carrasco, in preparation). However, little is known about its effect in children.4
suMMARY A double-blind crossover trial of ketotifen, a mast cell stabilising antihistamine, was performed in a group of 23 young asthmatic children. No useful prophylaxis against bronchoconstriction could be shown.
Ketotifen, an orally-active cycloheptathiophene antihistamine, stabilises mast cells in vitro.' This resembles the action of sodium cromoglycate in the prophylaxis of atopic asthma in cases where mast cell stabilisation prevents the release of histamine and other mediators on antigen challenge. Ketotifen has been shown to be effective in blocking antigeninduced bronchoconstriction in adults,2 and longterm studies have shown useful prophylaxis can be achieved in a proportion of atopic asthmatics with increasing effects over a period of up to 3 months3 (J Pepys, E Carrasco, in preparation). However, little is known about its effect in children. 4 Ketotifen is administered twice daily by mouth and in this respect it may be better than sodium cromoglycate, especially for children who are too young or too uncooperative to use a spinhaler. Apart from slight drowsiness, generally settling during the first few weeks of treatment, no significant side effects have been reported. We studied the usefulness of this drug in a group of young asthmatic children who were unable to use sodium cromoglycate by spinhaler satisfactorily.
Patients and methods
Twenty-three children (14 boys and 9 girls) completed a double-blind crossover trial with 2 months each on active and placebo treatment. The children ranged in age from 1 year 11 months to 5 years 3 months (median 3 years). Nineteen were between the 3rd and 97th centiles for height, 2 were above the 97th, and 2 were below the 3rd.5 One child was below the 3rd centile for weight but the other children were between the 3rd and 97th centiles.
Each one had suffered from recurrent wheezing attacks for between 10 months and 5 years. The onset of symptoms had been in the first year in 14 children, and in the second year in a further 8.
Eighteen had a family history of asthma or atopic disease. Questioning revealed that wheezing attacks were precipitated by upper respiratory infections in all 23, by obvious allergy in 9, and by exercise in 18. Twelve children suffered from eczema also. Fifteen had at some time been admitted to hospital for asthma, and 9 had received courses of oral steroids. Of the 11 children who had skin tests performed, 10 showed multiple positive reactions to common antigens.
At the start of the trial each child showed moderate or poor control of his asthma with routine treatment. Routine treatment was regular or intermittent oral salbutamol alone in 16, and accompanied by orciprenaline in 2, and theophylline in 2. One child had a nebuliser at home and was treated with regular nebulised cromoglycate (Intal) plus salbutamol. Two children were receiving steroids: alternate-day oral prednisolone on a regular basis in one and beclomethasone dipropionate (Becotide) rotacapsules in the other. Regular treatments were kept constant throughout the trial.
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The dose of ketotifen used during the active phase of the trial was 0 5 mg twice daily in infants over 10 kg (this is half the adult dose), and 0 25 mg twice daily in the 2 children who each weighed less than 10 kg. Response to treatment was assessed using diary cards recording wheeze and cough during the day and night. Symptoms were scored, 0 = well, 1 = mild, 2 = moderate, and 3 = severe, in each category. Bronchodilator consumption was also recorded. In those children old enough to co-operate, the peak expiratory flow rate (PEFR) was measured once daily-at 0800 hours. Any significant eventsuch as admission to hospital or the need for a short course of oral steroids-was noted.
Results
Mean symptom scores, PEFRs, and additional treatment requirements for the active and placebo periods are shown in the Parental preference 5 4 Results are shown ± I standard error where appropriate.
active period. Interestingly this child's condition was apparently improved by the active drug.
Discussion
In most parameters there was a small trend towards benefit with placebo, and we were unable to detect any evidence of useful prophylaxis with ketotifen. Ketotifen is closely related to pizotifen, which is marketed in West Germany as an appetite stimulant. We were interested to find a greater weight gain during the period of treatment.
Although no evidence of benefit has been shown, an orally active prophylactic agent would be most useful in this young age group and we feel that further work with higher doses of ketotifen is justified.
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